{"id":183999,"date":"2021-05-03T12:00:49","date_gmt":"2021-05-03T11:00:49","guid":{"rendered":"https:\/\/www.transcend.org\/tms\/?p=183999"},"modified":"2021-04-29T05:41:40","modified_gmt":"2021-04-29T04:41:40","slug":"preserving-intellectual-property-barriers-to-covid-19-vaccines-is-morally-wrong-and-foolish","status":"publish","type":"post","link":"https:\/\/www.transcend.org\/tms\/2021\/05\/preserving-intellectual-property-barriers-to-covid-19-vaccines-is-morally-wrong-and-foolish\/","title":{"rendered":"Preserving Intellectual Property Barriers to COVID-19 Vaccines Is Morally Wrong and Foolish"},"content":{"rendered":"

28 Apr 2021 – <\/em>New covid-19 variants are spreading quickly. An outbreak anywhere could lead to a more deadly or infectious strain hopping around the globe.<\/p>\n

So why, after three months of making great progress on domestic vaccination, has President Biden not ended a self-defeating policy from the Trump administration that hinders a global initiative to increase access to covid-19 vaccines and treatments? More than 100 countries support a temporary waiver<\/a> of some World Trade Organization rules that guarantee pharmaceutical firms monopoly control over how much medicine is produced, yet the United States remains opposed.<\/p>\n

Had WTO members agreed to waive aspects of its agreement on trade-related intellectual property for covid-related medicines when some countries proposed it last October, poor nations might not wait until 2024 for vaccines, as projected<\/a>.<\/p>\n

\"\"<\/a>

A woman receiving a COVID-19 vaccine in Karachi, Pakistan, on Monday 26 Apr 2021.
(photo: Akhtar Soomro\/Reuters)<\/p><\/div>\n

Waiving intellectual property rights so developing countries could produce more vaccines would make a big difference in reaching global herd immunity. Otherwise, the pandemic will rage largely unmitigated among a significant share of the world\u2019s population, resulting in increased deaths and a greater risk that a vaccine-resistant variant puts the world back on lockdown.<\/p>\n

Pharmaceutical corporations claim the problem is not intellectual property barriers, but that companies in developing nations don\u2019t have the skill to manufacture covid-19 vaccines based on new technologies. This is self-serving and wrong<\/a>.<\/p>\n

Firms in the Global South are already making covid-19 vaccines. For example, South Africa\u2019s Aspen Pharmacare<\/a> has produced hundreds of millions of doses of Johnson & Johnson\u2019s vaccine, even though only a fraction<\/a> of those went to South Africans. Other drug corporations simply refuse<\/a> to work with qualified manufacturers in developing countries, effectively blocking more production.<\/p>\n

These companies are focused not on global access but on sales in profitable markets<\/a>. This underscores why the \u201cthird way\u201d proposal<\/a> from WTO Director General Ngozi Okonjo-Iweala, in which she promotes more of the same old, industry-controlled voluntary deals, is a distraction and not a remedy<\/a>.<\/p>\n

Not one vaccine originator has shared technologies with poor countries through the World Health Organization\u2019s voluntary Covid-19 Technology Access Pool<\/a>. The global Covax<\/a> program, which aims to vaccinate 20 percent of developing countries\u2019 most vulnerable populations, has delivered about 38 million doses<\/a> to 100 countries<\/a>; meanwhile, the United States administers 3 million doses daily.<\/p>\n

There is no way to beat covid-19 without increasing vaccine production capacity. And some production must be in the Global South for a host of reasons, including that prompt suppression of new variants is how we avoid more deaths and quarantines.<\/p>\n

A waiver would immediately increase government leverage over vaccine makers that refuse to license the technology. Firms could choose to either expand production by negotiating with governments, alternative suppliers and global initiatives, or risk governments circumventing them and forcing the transfer of technology.<\/p>\n

A waiver would also provide legal certainty for governments and investors that are inclined to repurpose existing pharmaceutical manufacturing or build new facilities but are fearful of intellectual property liability. And it could boost production of covid-19 treatments unavailable in much of the world, as well as diagnostic tests and vaccine supply chain products.<\/p>\n

The principle that all countries should have access to intellectual property related to medicines has already been accepted by the international community. In the early 2000s, as millions without access to treatments died of AIDS, WTO members clarified that countries have \u201cflexibilities\u201d to issue compulsory licenses for medicines. The United States itself threatened to do<\/a> this for ciprofloxacin, a treatment for anthrax, during the 2001 scare. If there were ever a moment to invoke this principle, it is now.<\/p>\n

Unfortunately, the drug companies have consistently done whatever they can to preserve their monopoly control. Even today, as they battle the waiver and argue that existing compulsory licensing rights are sufficient, they lobby the U.S. government<\/a> to sanction countries that use that tool.<\/p>\n

These corporations have also undermined this option by building \u201cthickets<\/a>\u201d of intellectual property barriers. They fortify their monopolies by registering exclusive rights to industrial designs and undisclosed data, such as trade secrets and test data, in addition to numerous patents and copyrights for each medicine. Each element would require a license, and the WTO\u2019s flexibilities might not even encompass all of them.<\/p>\n

Making matters more difficult, \u201cproduct-by-product\u201d and \u201ccountry-by-country\u201d compulsory licensing is nigh impossible to coordinate across countries for medicines with complex global supply chains, such as covid-19 vaccines.<\/p>\n

Even more absurd is the argument from pharmaceutical companies that temporarily waiving their monopolies for covid-19 medicines would undermine their ability to respond to the next health crisis. Governments transferred more than $110 billion<\/a> to pharmaceutical firms to finance research and production, so companies face little risk while earning billions on vaccine sales. The market for covid-19 vaccines is literally the entire world, so any successful vaccine maker stands to profit handsomely<\/a> even with technology transfer.<\/p>\n

Any delay in ensuring the greatest availability of vaccines and therapeutics is morally wrong and foolish \u2014 both in terms of public health and the economy<\/a>. The waiver is a critical first step.<\/p>\n

______________________________________________<\/em><\/p>\n

\"\"<\/a><\/em>Joseph Eugene Stiglitz is an American economist and a professor at Columbia University. He is a recipient of the Nobel Prize in Economic Sciences (2001) and the John Bates Clark Medal (1979). He is a former senior vice president and chief economist of the World Bank and is known for his critical view of the management of globalization, free-market economists (whom he calls “free market fundamentalists”), and some international institutions like the International Monetary Fund and the World Bank.\u00a0Stiglitz is the author of <\/em>The Price of Inequality and <\/em>most recently of<\/em> People, Power, and Profits: Progressive Capitalism for an Age of Discontent<\/a>.<\/p>\n

Go to Original – readersupportednews.org<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

28 Apr 2021 – Why, after three months of making great progress on domestic vaccination, has President Biden not ended a self-defeating policy from the Trump administration that hinders a global initiative to increase access to covid-19 vaccines and treatments?<\/p>\n","protected":false},"author":4,"featured_media":181775,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[105],"tags":[232,1829,1868,1704,1705,1864,888],"class_list":["post-183999","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nobel-laureates","tag-capitalism","tag-coronavirus","tag-covid-19","tag-joseph-e-stiglitz","tag-nobel-economics-prize","tag-pandemic","tag-vaccines"],"_links":{"self":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/183999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/comments?post=183999"}],"version-history":[{"count":0,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/posts\/183999\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/media\/181775"}],"wp:attachment":[{"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/media?parent=183999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/categories?post=183999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transcend.org\/tms\/wp-json\/wp\/v2\/tags?post=183999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}